Carly D Miller, John R Lozada, Nicholas A Zorko, Andrew Elliott, Allison Makovec, Milan Radovich, Elisabeth I Heath, Neeraj Agarwal, Rana R McKay, Rohan Garje, Bruno R Bastos, Dave S Hoon, Jacob J Orme, Oliver Sartor, Ari Vanderwalde, Chadi Nabhan, George W Sledge, Eugene Shenderov, Scott M Dehm, Emil Lou, Jeffrey S Miller, Justin H Hwang, Emmanuel S Antonarakis
B7-H3 (CD276) is a transmembrane glycoprotein of the B7 immune checkpoint superfamily that has emerged as a promising therapeutic target. To better understand the applicability of B7-H3-directed therapies, we analyzed 156,791 samples comprising 50 cancer types to interrogate the clinical, genomic, transcriptomic, and immunological correlates of B7-H3 mRNA expression. DNA (592-gene/whole-exome) and RNA (whole-transcriptome) sequencing was performed from samples submitted to Caris Life Sciences (Phoenix, AZ)...
May 6, 2024: Cancer Res Commun